FDA faults Japan­ese man­u­fac­tur­er with da­ta breach, con­t­a­m­i­nat­ed in­jecta­bles

The FDA has come down hard on a Japan­ese man­u­fac­tur­er, with cGMP fail­ures that in­clude batch dis­crep­an­cies left with­out in­ves­ti­ga­tion, da­ta breach­es left un­ad­dressed and the ma­nip­u­la­tion of con­tact plate mea­sure­ments.

Toy­obo Co. re­ceived a warn­ing let­ter on Aug. 19. If it can­not cor­rect the vi­o­la­tions, the FDA can refuse the im­port of drugs man­u­fac­tured at the Shi­ga site in­to the US. Toy­obo has 15 days to re­spond to the let­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER